Cargando…

Rimonabant: From RIO to Ban

Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century. The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sam, Amir H., Salem, Victoria, Ghatei, Mohammad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136184/ https://www.ncbi.nlm.nih.gov/pubmed/21773005 http://dx.doi.org/10.1155/2011/432607

Ejemplares similares

Rimonabant for treating tobacco dependence
por: Steinberg, Michael B, et al.
Publicado: (2007)

Rimonabant, Gastrointestinal Motility and Obesity
por: Sun, Yan, et al.
Publicado: (2012)

Rimonabant-induced depression in schizophrenia
por: Arasappa, Rashmi, et al.
Publicado: (2014)

The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant
por: Murro, Ada Letícia B
Publicado: (2009)

Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome
por: Waterlow, Mark, et al.
Publicado: (2007)

Potential Implications of Rimonabant on Age-Related Oxidative Stress and Inflammation
por: Szabó, Renáta, et al.
Publicado: (2022)

Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results
por: Fernández-Fernández, Cristina, et al.
Publicado: (2014)

Can antidepressants unlock prescription of rimonabant in the fight against COVID-19?
por: Salles, Juliette, et al.
Publicado: (2021)

Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data
por: Bronander, Kirk A, et al.
Publicado: (2007)

Rimonabant and Cannabidiol Rewrite the Interactions between Breast Cancer Cells and Tumor Microenvironment
por: Proto, Maria Chiara, et al.
Publicado: (2023)

Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease
por: Jorgačević, Bojan, et al.
Publicado: (2015)

Food Advertisements: To Ban or Not to Ban?
por: Alkharfy, Khalid M.
Publicado: (2011)

Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial
por: Hollander, Priscilla A., et al.
Publicado: (2010)

RP-HPLC Method Development and Its Validation for Quantitative Determination of Rimonabant in Human Plasma
por: Bankey, Shravan, et al.
Publicado: (2012)

Smoking: Bans, Bans, Good for the Heart!
por: Burton, Adrian
Publicado: (2006)

Plasma and Liver Lipidomics Response to an Intervention of Rimonabant in ApoE*3Leiden.CETP Transgenic Mice
por: Hu, Chunxiu, et al.
Publicado: (2011)

Effects of the cannabinoid CB(1) receptor antagonist rimonabant on distinct measures of impulsive behavior in rats
por: Pattij, Tommy, et al.
Publicado: (2007)

Rimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids
por: Fiore, Donatella, et al.
Publicado: (2018)

Toward an Asbestos Ban in the United States
por: Lemen, Richard A., et al.
Publicado: (2017)

Different Transcriptional Control of Metabolism and Extracellular Matrix in Visceral and Subcutaneous Fat of Obese and Rimonabant Treated Mice
por: Poussin, Carine, et al.
Publicado: (2008)

Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology
por: Chavez-Tapia, Norberto C, et al.
Publicado: (2009)

SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients : Effects of monotherapy with rimonabant, the first selective CB(1) receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes
por: Rosenstock, Julio, et al.
Publicado: (2008)

Influence of rimonabant treatment on peripheral blood mononuclear cells; flow cytometry analysis and gene expression profiling
por: Almestrand, Stefan, et al.
Publicado: (2015)

Effect of Intermittent Hypoxia and Rimonabant on Glucose Metabolism in Rats: Involvement of Expression of GLUT4 in Skeletal Muscle
por: Wang, Xiaoya, et al.
Publicado: (2015)

Rimonabant-Based Compounds Bearing Hydrophobic Amino Acid Derivatives as Cannabinoid Receptor Subtype 1 Ligands
por: Dvorácskó, Szabolcs, et al.
Publicado: (2023)

Bromoxynil Ban
Publicado: (1998)

Shigeru Ban
por: Ban, Shigeru, 1957-
Publicado: (1997)

Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer
por: Proto, Maria Chiara, et al.
Publicado: (2017)

Context-dependent effects of the CB1 receptor antagonist rimonabant on morphine-induced behavioral sensitization in female mice
por: Marinho, Eduardo A. V., et al.
Publicado: (2023)

Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors
por: Mollica, Adriano, et al.
Publicado: (2017)

CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced renal injury in rats
por: Zhao, Li, et al.
Publicado: (2021)

Health effects of banning beehive coke ovens and implementation of the ban in China
por: Xu, Yang, et al.
Publicado: (2018)

California bans pesticides.
Publicado: (1996)

The G protein-coupled receptor-associated protein 1 (GASP-1) regulates rimonabant-induced downregulation of GPR55
por: Kargl, Julia, et al.
Publicado: (2011)

Reduced Food Intake is the Major Contributor to the Protective Effect of Rimonabant on Islet in Established Obesity-Associated Type 2 Diabetes
por: Jin, Sang-Man, et al.
Publicado: (2013)

CB1 Receptor-Dependent and Independent Induction of Lipolysis in Primary Rat Adipocytes by the Inverse Agonist Rimonabant (SR141716A)
por: Müller, Günter A., et al.
Publicado: (2020)

Smoking in Correctional Settings Worldwide: Prevalence, Bans, and Interventions
por: Spaulding, Anne C, et al.
Publicado: (2018)

Ban on Dextropropoxyphene is Unjustifiable
por: Butola, Savita, et al.
Publicado: (2015)

QnAs with Nenad Ban
por: Ahmed, Farooq
Publicado: (2022)

Tobacco product menthol and flavour bans: their utility for LMIC and lessons from the EU ban: Rosemary Hiscock
por: Hiscock, R, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m3bnloe9gsrku26r3bscjvgut6